A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

BMC Psychiatry

Linda Mele²  Eunhee Hwang²  Karen A Tourian²  Michael R Liebowitz¹ 

[1] Columbia University, 134 East 93rd Street, Suite 201B, New York, NY, 10128, USA;Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA

关键词: Drug safety;    Treatment;    Efficacy;    Antidepressive agents;    Adult;    Depression;   

Others  :  1124100
DOI  :  10.1186/1471-244X-13-94

 received in 2012-06-29, accepted in 2013-02-27,  发布年份 2013

【 摘 要 】

Background

In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and 50-mg/day desvenlafaxine vs placebo for the treatment of major depressive disorder.

Methods

Adult outpatients with DSM-IV–defined major depressive disorder and a 17-item Hamilton Rating Scale for Depression (HAM-D₁₇) total score ≥20 were randomly assigned to receive placebo or desvenlafaxine (10 or 50 mg/day) after a 6- to 14-day single-blind placebo lead-in period in an 8-week, phase 3, fixed-dose trial. The primary efficacy measure was change from baseline in the HAM-D₁₇ score analyzed using analysis of covariance. Efficacy analyses were conducted with the intent-to-treat population, using the last observation carried forward.

Results

The intent-to-treat population included 673 patients. Change from baseline to final evaluation in adjusted HAM-D₁₇ total scores was not significantly different comparing desvenlafaxine 10 mg/day (-9.28) and desvenlafaxine 50 mg/day (-8.92) with placebo (-8.42). There were no differences among treatment groups in the rates of treatment response or remission. Discontinuations due to adverse events occurred in 1.8%, 0.9%, and 1.8% of patients in the placebo and desvenlafaxine 10- and 50-mg/day groups, respectively. Overall rates of treatment-emergent adverse events with both doses were similar to placebo.

Conclusions

Both doses of desvenlafaxine failed to separate from placebo. However, in a companion study reported separately, desvenlafaxine 50 mg, but not 25 mg, separated from placebo. Taken together, these studies suggest that 50 mg is the minimum effective dose of desvenlafaxine for the treatment of major depressive disorder.

ClinicalTrials.gov Identifier

NCT00863798 http://clinicaltrials.gov/ct2/show/NCT00863798?term=00863798&rank=1 webcite.

【 授权许可】

   
2013 Liebowitz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gelenberg AJ: The prevalence and impact of depression. J Clin Psychiatr 2010, 71:e06.
• [2]Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
• [3]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Washington, DC: American Psychiatric Association; 1994.
• [4]Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc; 2011.
• [5]Liebowitz MR, Yeung PP, Entsuah R: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatr 2007, 68:1663-1672.
• [6]DeMartinis NA, Yeung PP, Entsuah R, Manley AL: A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatr 2007, 68:677-688.
• [7]Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007, 22:338-347.
• [8]Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA: Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008, 23:243-253.
• [9]Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA: Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008, 24:1877-1890.
• [10]Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D: Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009, 31(Pt 1):1405-1423.
• [11]Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK: A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009, 14:41-50.
• [12]Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C: Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010, 30:18-24.
• [13]Iwata N, Tourian KA, Hwang E, Mele L, Vialet C, for the Study 3359 Investigators: Efficacy and safety of desvenlafaxine 25 and 50 mg/d in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013, 19:5-14.
• [14]Guy W: Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976:217-222.
• [15]Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
• [16]Khan A, Detke M, Khan SR, Mallinckrodt C: Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003, 191:211-218.
• [17]Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53.
• [18]Moller HJ: Rating depressed patients: observer- vs self-assessment. Eur Psychiatr 2000, 15:160-172.
• [19]Bech P: Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006, 8:207-215.
• [20]Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A: Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol 2011, 26:75-83.
• [21]Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S: Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. Prim Care Companion J Clin Psychiatr 2009, 11:8-15.